Researchers from Universidade Federal de Minas Gerais have published details on the discovery of novel anti-SARS-CoV-2 compounds with robust antiviral activity.
Reithera Srl, The Ragon Institute of Mass General, MIT and Harvard, and IAVI have established a collaboration to develop a novel HIV vaccine candidate based on gorilla adenoviral vector (GRAd), with funding by the Bill & Melinda Gates Foundation.
Vesper Bio ApS has been awarded a grant worth $873,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to assess sortilin inhibition in Parkinson’s disease.
Collagen prolyl 4-hydroxylase (P4H) is an α-ketoglutarate (α-KG)-dependent dioxygenase, and prolyl 4-hydroxylase subunit α1 (P4HA1) is the major isoform among the catalytic subunits of P4H. It has been previously demonstrated that P4HA1 promotes angiogenesis in tumors, and bioinformatics analysis has identified P4HA1 as a glycolysis-related gene in various cancers.
Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease.
Arcus Biosciences Inc. has synthesized tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of viral infection, cancer and fibrosis.
Axonis Therapeutics Inc. has disclosed dual specificity mitogen-activated protein kinase kinase (MAP2K7; MKK7) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, spinal cord injury, multiple sclerosis, neurodegeneration, lysosomal storage, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease, among others.
Proteinlogic Ltd. and Stellenbosch University have received a $1.35 million grant from the Bill & Melinda Gates Foundation to develop a blood test to monitor treatment responses to tuberculosis (TB) antimicrobial chemotherapy.
Despite treatment with temozolomide and radiation therapy, patients with glioblastoma usually develop refractory disease, and thus have a poor prognosis (median overall survival of 15 months); here, the DNA damage response (DDR) mechanism shown by cancer cells plays a key role.
RSS
